◎ Sugi Atlas

Atlas / Gene / CNN2

CNN2

gene
On this page

Summary

CNN2 (calponin 2, HGNC:2156) is a protein-coding gene on chromosome 19p13.3, encoding Calponin-2 (Q99439). Thin filament-associated protein that is implicated in the regulation and modulation of smooth muscle contraction.

The protein encoded by this gene, which can bind actin, calmodulin, troponin C, and tropomyosin, may function in the structural organization of actin filaments. The encoded protein could play a role in smooth muscle contraction and cell adhesion. Several pseudogenes of this gene have been identified, and are present on chromosomes 1, 2, 3, 6, 9, 11, 13, 15, 16, 21 and 22. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 1265 — RefSeq curated summary.

At a glance

  • GWAS associations: 16
  • Clinical variants (ClinVar): 67 total — 2 pathogenic
  • Druggable target: yes
  • MANE Select transcript: NM_004368

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:2156
Approved symbolCNN2
Namecalponin 2
Location19p13.3
Locus typegene with protein product
StatusApproved
Ensembl geneENSG00000064666
Ensembl biotypeprotein_coding
OMIM602373
Entrez1265

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 19 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000263097, ENST00000348419, ENST00000562015, ENST00000562075, ENST00000562958, ENST00000564572, ENST00000565096, ENST00000566695, ENST00000568865, ENST00000569352, ENST00000606983, ENST00000607102, ENST00000865315, ENST00000865316, ENST00000926772, ENST00000926773, ENST00000926774, ENST00000926775, ENST00000926776, ENST00000926777, ENST00000926778, ENST00000926779

RefSeq mRNA: 4 — MANE Select: NM_004368 NM_001303499, NM_001303501, NM_004368, NM_201277

CCDS: CCDS12053, CCDS12054, CCDS77204, CCDS77205

Canonical transcript exons

ENST00000263097 — 7 exons

ExonStartEnd
ENSE0000369506210310711031192
ENSE0000369588610364161036562
ENSE0000369672710325591032696
ENSE0000369866210266081026724
ENSE0000373649910323921032458
ENSE0000373980310361301036246
ENSE0000385019010376251039065

Expression profiles

Bgee: expression breadth ubiquitous, 246 present calls, max score 98.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 188.3678 / max 1613.7939, expressed in 1819 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter IDTPM avgSamples expressed
172832183.48511819
1728373.41001146
2086260.5740367
1728300.4114246
1728310.2706128
1728350.216861

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
granulocyteCL:000009498.61gold quality
stromal cell of endometriumCL:000225598.43gold quality
right ovaryUBERON:000211898.27gold quality
right lungUBERON:000216798.17gold quality
lower esophagus mucosaUBERON:003583498.11gold quality
left ovaryUBERON:000211998.10gold quality
left uterine tubeUBERON:000130398.09gold quality
bloodUBERON:000017897.91gold quality
upper lobe of left lungUBERON:000895297.88gold quality
right coronary arteryUBERON:000162597.85gold quality
ascending aortaUBERON:000149697.67gold quality
thoracic aortaUBERON:000151597.67gold quality
upper lobe of lungUBERON:000894897.49gold quality
aortaUBERON:000094797.32gold quality
gall bladderUBERON:000211097.29gold quality
body of uterusUBERON:000985397.22gold quality
popliteal arteryUBERON:000225097.18gold quality
tibial arteryUBERON:000761097.18gold quality
ectocervixUBERON:001224997.06gold quality
spleenUBERON:000210697.02gold quality
descending thoracic aortaUBERON:000234597.02gold quality
buccal mucosa cellCL:000233697.01gold quality
left coronary arteryUBERON:000162696.92gold quality
esophagus mucosaUBERON:000246996.81gold quality
mucosa of stomachUBERON:000119996.76gold quality
lymph nodeUBERON:000002996.75gold quality
minor salivary glandUBERON:000183096.70gold quality
leukocyteCL:000073896.69gold quality
monocyteCL:000057696.67gold quality
olfactory segment of nasal mucosaUBERON:000538696.64gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 4.

ExperimentMarker?Max mean expression
E-MTAB-6819yes441.49
E-HCAD-10yes61.81
E-CURD-122yes16.15
E-MTAB-7606no1099.59
E-CURD-97no1016.32
E-CURD-120no10.31
E-ANND-3no0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1

miRNA regulators (miRDB)

46 targeting CNN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-4481100.0066.421669
HSA-MIR-453499.9966.581907
HSA-MIR-4725-3P99.9669.532520
HSA-MIR-6780B-5P99.9669.602562
HSA-MIR-365899.9673.874379
HSA-MIR-6825-5P99.9669.813431
HSA-MIR-23A-3P99.9574.243163
HSA-MIR-23B-3P99.9574.243163
HSA-MIR-23C99.9573.923192
HSA-MIR-808299.9567.271170
HSA-MIR-6721-5P99.9368.922981
HSA-MIR-427199.8868.322244
HSA-MIR-449299.8768.253611
HSA-MIR-444799.8567.812900
HSA-MIR-3150A-3P99.7664.441640
HSA-MIR-6763-5P99.7664.681767
HSA-MIR-317599.6566.302031
HSA-MIR-497-3P99.6169.711990
HSA-MIR-4649-3P99.5666.901783
HSA-MIR-608199.4866.071446
HSA-MIR-127599.4767.902749
HSA-MIR-133A-3P99.2771.531270
HSA-MIR-133B99.2771.531270
HSA-MIR-329-5P99.2768.111597
HSA-MIR-548AS-3P99.1269.122294
HSA-MIR-625-5P99.0268.642031
HSA-MIR-1228-3P99.0066.53857
HSA-MIR-143-5P98.9868.87946
HSA-MIR-319698.9663.91326
HSA-MIR-331-3P98.7664.91793

Literature-anchored findings (GeneRIF, showing 7)

  • h2-Calponin gene expression is further affected by the treatment of cells with Notch inhibitor and activator, suggesting an upstream signaling mechanism. (PMID:24285540)
  • High Calponin-h2 serum levels are associated with breast cancer. (PMID:25099617)
  • our results demonstrated that knockdown of endogenous CNN2 in AGS cells could significantly activate cell apoptosis pathway and therefore suppress cell growth in vitro. The deletion of CNN2 might be a potential therapeutic approach to inhibit aggressive growth of gastric cancer. (PMID:28714360)
  • Study in human hepatocellular carcinoma cell line and xenograft mouse model shows that CNN2 plays an important role in tumor growth and metastasis, possibly through MEK1/2-ERK1/2 signaling pathway. (PMID:29333089)
  • A rapid degradation of calponin 2 is required for cytokinesis. (PMID:34133238)
  • Serum calponin 2 is a novel biomarker of tubal ectopic pregnancy. (PMID:34217487)
  • Calponin 2 regulates ketogenesis to mitigate acute kidney injury. (PMID:37751293)

Cross-species orthologs

9 orthologs

OrganismSymbolGene ID
danio_reriocnn2ENSDARG00000035858
mus_musculusCnn2ENSMUSG00000004665
rattus_norvegicusCnn2ENSRNOG00000043044
drosophila_melanogasterMp20FBGN0002789
drosophila_melanogasterChd64FBGN0035499
caenorhabditis_eleganscpn-1WBGENE00000777
caenorhabditis_elegansWBGENE00000778
caenorhabditis_eleganscpn-3WBGENE00000779
caenorhabditis_eleganscpn-4WBGENE00000780

Paralogs (5): CNN3 (ENSG00000117519), CNN1 (ENSG00000130176), TAGLN3 (ENSG00000144834), TAGLN (ENSG00000149591), TAGLN2 (ENSG00000158710)

Protein

Protein identifiers

Calponin-2 — Q99439 (reviewed: Q99439)

Alternative names: Calponin H2, smooth muscle, Neutral calponin

All UniProt accessions (9): Q99439, A0A087WV51, A0A087X1X5, A0A087X271, B4DDF4, B4DUT8, H3BVI6, K7ES69, U3KPS3

UniProt curated annotations — full annotation on UniProt →

Function. Thin filament-associated protein that is implicated in the regulation and modulation of smooth muscle contraction. It is capable of binding to actin, calmodulin and tropomyosin. The interaction of calponin with actin inhibits the actomyosin Mg-ATPase activity.

Tissue specificity. Heart and smooth muscle.

Similarity. Belongs to the calponin family.

Isoforms (2)

UniProt IDNamesCanonical?
Q99439-11yes
Q99439-22

RefSeq proteins (4): NP_001290428, NP_001290430, NP_004359, NP_958434 (=MANE)

Domains & families (InterPro)

IDNameType
IPR000557Calponin_repeatRepeat
IPR001715CH_domDomain
IPR001997Calponin/LIMCH1Family
IPR003096SM22_calponinFamily
IPR036872CH_dom_sfHomologous_superfamily
IPR050606Calponin-likeFamily

Pfam: PF00307, PF00402

UniProt features (25 total): helix 7, sequence conflict 5, modified residue 4, repeat 3, initiator methionine 1, chain 1, splice variant 1, domain 1, strand 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDBMethodResolution (Å)
1WYNSOLUTION NMR

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q99439-F168.620.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 138, 2, 8, 25

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

IDPathway
R-HSA-6798695Neutrophil degranulation
R-HSA-8950505Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation

MSigDB gene sets: 268 (showing top): HORIUCHI_WTAP_TARGETS_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, REACTOME_INNATE_IMMUNE_SYSTEM, WWTAAGGC_UNKNOWN, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, GOCC_SECRETORY_GRANULE, GOBP_CELLULAR_RESPONSE_TO_EXTERNAL_STIMULUS, LFA1_Q6, GOBP_NEGATIVE_REGULATION_OF_ENDOCYTOSIS, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, SRF_Q5_01, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION

GO Biological Process (15): phagocytosis (GO:0006909), cytoskeleton organization (GO:0007010), actin filament organization (GO:0007015), positive regulation of gene expression (GO:0010628), hemopoiesis (GO:0030097), actomyosin structure organization (GO:0031032), regulation of mononuclear cell proliferation (GO:0032944), regulation of actin filament-based process (GO:0032970), wound healing (GO:0042060), negative regulation of phagocytosis (GO:0050765), establishment of localization in cell (GO:0051649), cellular response to mechanical stimulus (GO:0071260), macrophage migration (GO:1905517), negative regulation of macrophage migration (GO:1905522), regulation of leukocyte proliferation (GO:0070663)

GO Molecular Function (5): actin binding (GO:0003779), calmodulin binding (GO:0005516), cadherin binding (GO:0045296), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (9): stress fiber (GO:0001725), extracellular region (GO:0005576), cytoskeleton (GO:0005856), cell-cell junction (GO:0005911), focal adhesion (GO:0005925), actin cytoskeleton (GO:0015629), membrane (GO:0016020), specific granule lumen (GO:0035580), tertiary granule lumen (GO:1904724)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Innate Immune System1
Interleukin-12 signaling1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
actin cytoskeleton organization2
cellular anatomical structure2
endocytosis1
organelle organization1
supramolecular fiber organization1
gene expression1
regulation of gene expression1
positive regulation of macromolecule biosynthetic process1
cell development1
mononuclear cell proliferation1
regulation of leukocyte proliferation1
actin filament-based process1
regulation of cellular process1
response to wounding1
tissue regeneration1
phagocytosis1
negative regulation of endocytosis1
regulation of phagocytosis1
establishment of localization1
cellular localization1
response to mechanical stimulus1
cellular response to abiotic stimulus1
cellular response to external stimulus1
mononuclear cell migration1
myeloid leukocyte migration1
negative regulation of mononuclear cell migration1
macrophage migration1
regulation of macrophage migration1
regulation of cell population proliferation1
leukocyte proliferation1
cytoskeletal protein binding1
protein binding1
cell adhesion molecule binding1
actin binding1
protein-containing complex binding1
binding1
actomyosin1
contractile actin filament bundle1
intracellular membraneless organelle1
anchoring junction1

Protein interactions and networks

STRING

3320 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
CNN2VCLP18206662
CNN2CALML4Q96GE6647
CNN2CALM1P02593546
CNN2CALML3P27482541
CNN2CALML5Q9NZT1541
CNN2CALML6Q8TD86521
CNN2MYH11P35749480
CNN2SRFP11831472
CNN2CALD1Q05682469
CNN2FLNAP21333458
CNN2MYOCDQ8IZQ8453
CNN2SMTNP53814435
CNN2VAV1P15498429
CNN2FLNCQ14315421
CNN2TPM4P07226400

IntAct

54 interactions, top by confidence:

ABTypeScore
CFTRESYT2psi-mi:“MI:0914”(association)0.710
CDALIN7Apsi-mi:“MI:0914”(association)0.640
CFTRHAX1psi-mi:“MI:0914”(association)0.610
NAGKZBTB43psi-mi:“MI:0914”(association)0.530
CNN2ATE1psi-mi:“MI:0914”(association)0.530
RAB4ACHMLpsi-mi:“MI:0914”(association)0.530
HSPA2DNAJC13psi-mi:“MI:0914”(association)0.530
AP3D1psi-mi:“MI:0914”(association)0.460
IPO5psi-mi:“MI:0914”(association)0.350
PGRMC1psi-mi:“MI:0914”(association)0.350
HIF1ANCNOT1psi-mi:“MI:0914”(association)0.350
EGLN3FAM168Bpsi-mi:“MI:0914”(association)0.350
PLEKHA7PLEKHG3psi-mi:“MI:0914”(association)0.350
ZDHHC5HACD3psi-mi:“MI:0914”(association)0.350
ZDHHC5IGKV2D-24psi-mi:“MI:0914”(association)0.350
PIK3C2Apsi-mi:“MI:0914”(association)0.350
AGPSpsi-mi:“MI:0914”(association)0.350
PLEKHG3psi-mi:“MI:0914”(association)0.350
ATG16L1ESYT2psi-mi:“MI:0914”(association)0.350
ST6GALNAC6A2ML1psi-mi:“MI:0914”(association)0.350
MTSS2CHEK1psi-mi:“MI:0914”(association)0.350
DDX28UBA6psi-mi:“MI:0914”(association)0.350
DND1UBA6psi-mi:“MI:0914”(association)0.350
GAB2UBA6psi-mi:“MI:0914”(association)0.350
HSPA8PLEKHG3psi-mi:“MI:0914”(association)0.350

BioGRID (103): CNN3 (Affinity Capture-MS), ATE1 (Affinity Capture-MS), TRAPPC9 (Affinity Capture-MS), ALAD (Affinity Capture-MS), ALDH8A1 (Co-fractionation), MTAP (Co-fractionation), SF1 (Co-fractionation), CNN2 (Affinity Capture-MS), CNN2 (Proximity Label-MS), CNN3 (Affinity Capture-MS), CNN2 (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), ATE1 (Affinity Capture-MS), ALAD (Affinity Capture-MS), TRAPPC4 (Affinity Capture-MS)

ESM2 similar proteins: E2RU10, O14185, O88818, P19966, P26932, P31232, P34512, P37397, P37802, P37803, P37804, P37805, P48608, P51911, P91529, Q01995, Q02328, Q08091, Q08092, Q08093, Q08094, Q08290, Q08873, Q15417, Q2HJ38, Q32L92, Q3SYU6, Q3ZBY2, Q4R5J4, Q550R2, Q5E9F5, Q5R6R2, Q5RFN6, Q5XFX0, Q63598, Q7XJ60, Q7XVN7, Q7YRL2, Q8WTJ4, Q99439

Diamond homologs: B9EUM5, O14185, O14188, P14318, P19966, P26932, P31232, P37397, P37802, P37803, P37804, P37805, P46940, P51911, Q01995, Q08091, Q08092, Q08093, Q08094, Q08290, Q08873, Q12280, Q15052, Q15417, Q24799, Q2HJ38, Q32L92, Q3SYU6, Q3ZBY2, Q4R5J4, Q54TK8, Q55E26, Q55GV9, Q5AH02, Q5E9F5, Q5R6R2, Q5RFN6, Q5XFX0, Q5XXR3, Q5ZLR6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic2
Likely pathogenic0
Uncertain significance49
Likely benign1
Benign0

Top pathogenic / likely-pathogenic (2)

Variant IDHGVSClassification
1696851NM_004368.4(CNN2):c.797G>A (p.Arg266Gln)Pathogenic
1696852NM_004368.4(CNN2):c.787G>A (p.Gly263Ser)Pathogenic

SpliceAI

1214 predictions. Top by Δscore:

VariantEffectΔscore
19:1026723:GG:Gdonor_gain1.0000
19:1026724:GG:Gdonor_gain1.0000
19:1026724:GGTG:Gdonor_loss1.0000
19:1026725:G:GGdonor_gain1.0000
19:1026726:T:Adonor_loss1.0000
19:1031067:CCA:Cacceptor_loss1.0000
19:1031069:A:ACacceptor_loss1.0000
19:1031069:A:AGacceptor_gain1.0000
19:1031070:G:GTacceptor_gain1.0000
19:1031070:GC:Gacceptor_gain1.0000
19:1031070:GCT:Gacceptor_gain1.0000
19:1031070:GCTC:Gacceptor_gain1.0000
19:1031070:GCTCC:Gacceptor_gain1.0000
19:1031188:TGCAC:Tdonor_gain1.0000
19:1031189:GCAC:Gdonor_gain1.0000
19:1031189:GCACG:Gdonor_gain1.0000
19:1031190:CAC:Cdonor_gain1.0000
19:1031190:CACGT:Cdonor_loss1.0000
19:1031191:AC:Adonor_gain1.0000
19:1031191:ACGT:Adonor_loss1.0000
19:1031192:CGTG:Cdonor_loss1.0000
19:1031193:G:GGdonor_gain1.0000
19:1031193:GTG:Gdonor_loss1.0000
19:1032370:C:CAacceptor_gain1.0000
19:1032376:A:AGacceptor_gain1.0000
19:1032376:AT:Aacceptor_gain1.0000
19:1032376:ATGTT:Aacceptor_gain1.0000
19:1032377:T:Gacceptor_gain1.0000
19:1032377:T:TAacceptor_gain1.0000
19:1032380:T:Aacceptor_gain1.0000

AlphaMissense

2040 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
19:1026699:G:AG13E1.000
19:1031177:G:AG57E1.000
19:1032450:T:AW82R1.000
19:1032450:T:CW82R1.000
19:1032452:G:CW82C1.000
19:1032452:G:TW82C1.000
19:1032638:T:CL111P1.000
19:1036419:G:CG171R1.000
19:1036442:G:CQ178H1.000
19:1036442:G:TQ178H1.000
19:1036462:G:AG185D1.000
19:1036471:G:CR188T1.000
19:1036471:G:TR188M1.000
19:1036472:G:CR188S1.000
19:1036472:G:TR188S1.000
19:1036539:G:CG211R1.000
19:1026698:G:AG13R0.999
19:1026698:G:CG13R0.999
19:1031108:T:AL34H0.999
19:1031108:T:CL34P0.999
19:1031116:T:AW37R0.999
19:1031116:T:CW37R0.999
19:1031168:T:CL54P0.999
19:1031177:G:TG57V0.999
19:1031186:T:CL60S0.999
19:1032394:T:CL63P0.999
19:1032451:G:CW82S0.999
19:1032560:T:CL85P0.999
19:1032569:T:CL88P0.999
19:1032622:T:CF106L0.999

dbSNP variants (sampled 300 via entrez): RS1000049566 (19:1028702 G>C,T), RS1000162724 (19:1028096 G>A), RS1000207698 (19:1037211 C>T), RS1000277113 (19:1035236 C>G,T), RS1000407997 (19:1039274 C>G,T), RS1000715141 (19:1038378 A>G), RS1000886683 (19:1039380 C>T), RS1001456279 (19:1027438 G>A), RS1001663681 (19:1028491 C>A,T), RS1001772661 (19:1035655 G>A,T), RS1001789756 (19:1026486 A>G), RS1001882641 (19:1031408 G>A), RS1002009702 (19:1028716 G>A), RS1002048994 (19:1032034 C>A), RS1002673768 (19:1038839 G>T)

Disease associations

OMIM: gene MIM:602373 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

StudyTraitp-value
GCST003219_41Advanced age-related macular degeneration3.000000e-08
GCST004599_138Mean platelet volume1.000000e-11
GCST004610_87White blood cell count3.000000e-10
GCST004614_71Granulocyte count3.000000e-10
GCST004617_129Eosinophil percentage of granulocytes5.000000e-09
GCST004625_204Monocyte count3.000000e-11
GCST90002381_560Eosinophil count2.000000e-09
GCST90002382_495Eosinophil percentage of white cells1.000000e-24
GCST90002388_521Lymphocyte count2.000000e-09
GCST90002393_627Monocyte count8.000000e-28
GCST90002395_295Mean platelet volume5.000000e-10
GCST90002398_97Neutrophil count5.000000e-24
GCST90002399_211Neutrophil percentage of white cells5.000000e-11
GCST90002400_256Plateletcrit7.000000e-12
GCST90002404_199Red cell distribution width5.000000e-22
GCST90002407_171White blood cell count2.000000e-29

EFO canonical traits (11, from GWAS)

EFO IDTrait name
EFO:1001492atrophic macular degeneration
EFO:0007987granulocyte count
EFO:0007996eosinophil percentage of granulocytes
EFO:0005091monocyte count
EFO:0004842eosinophil count
EFO:0007991eosinophil percentage of leukocytes
EFO:0004587lymphocyte count
EFO:0004833neutrophil count
EFO:0007990neutrophil percentage of leukocytes
EFO:0007985platelet crit
EFO:0009188Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295930 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
bisphenol Aaffects cotreatment, increases methylation, decreases expression3
sodium arseniteaffects cotreatment, decreases expression, increases abundance, increases expression2
(+)-JQ1 compounddecreases expression2
Rotenoneincreases expression2
Tretinoinincreases expression2
1-Methyl-4-phenylpyridiniumincreases expression2
Genisteindecreases expression, increases reaction2
Particulate Matterincreases abundance, affects cotreatment, decreases expression2
bisphenol Fincreases expression1
dicrotophosincreases expression1
triphenyl phosphateaffects expression1
propionaldehydeincreases expression1
beta-lapachonedecreases expression1
cobaltous chloridedecreases expression1
butyraldehydeincreases expression1
perfluorooctanoic aciddecreases expression1
zinc chromatedecreases expression, increases abundance1
isobutyl alcoholincreases abundance, affects cotreatment, decreases expression1
chromium hexavalent iondecreases expression, increases abundance1
perfluorooctane sulfonic aciddecreases expression1
entinostatincreases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, decreases expression1
nutlin 3affects cotreatment, increases secretion1
abrinedecreases expression1
eprenetapoptaffects expression, affects reaction1
LDN 193189affects cotreatment, decreases expression1
bisphenol AFincreases expression1
Fulvestrantaffects cotreatment, increases methylation1
Leflunomideincreases expression1
Air Pollutantsdecreases expression, increases abundance1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4118779BindingBinding affinity to CNN2 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assayStudies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 78

This page pulls from 78 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot